Refractive errors represent a group of vision disorders where the eye is unable to properly focus light on the retina, leading to blurred or distorted vision. These conditions include myopia, hyperopia, astigmatism, and presbyopia, often categorized under common vision correction disorders and ocular refractive conditions. As per findings reported by Dr. Moushumi Majumder et al., 2025, refractive errors contribute to nearly half of vision impairment cases across developed regions. According to the refractive errors pipeline analysis, the pipeline is gradually expanding, with increasing emphasis on pharmacological approaches aimed at controlling disease progression. Growing factors such as rising screen exposure, aging populations, and unmet clinical needs are accelerating research activity, thereby fostering innovation and sustained pipeline expansion.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to refractive errors.
Refractive errors treatment approaches include prescription eyeglasses and contact lenses, as well as emerging non-invasive eye treatment options and pharmacological therapies designed to slow disease progression. Surgical interventions such as laser-assisted in situ keratomileusis are also widely used to improve retinal focus. In June 2023, Vyluma announced United States Food and Drug Administration acceptance of the New Drug Application for NVK002, a low-dose atropine eye drops for pediatric myopia. This development reflects significant progress in pediatric myopia management drugs and highlights advancements in addressing unmet needs in controlling myopia progression among children.
Report Coverage
The Refractive Errors Pipeline Analysis Report gives comprehensive insights into refractive errors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for refractive errors. The refractive errors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The refractive errors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with refractive errors treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to refractive errors.
Refractive Errors Pipeline Outlook
Refractive errors are among the most prevalent global vision impairment causes, arising due to irregularities in eye structure such as axial length, corneal curvature, or lens flexibility. These structural variations disrupt the way light is refracted within the eye, leading to blurred or impaired vision.Refractive errors treatment approaches include prescription eyeglasses and contact lenses, as well as emerging non-invasive eye treatment options and pharmacological therapies designed to slow disease progression. Surgical interventions such as laser-assisted in situ keratomileusis are also widely used to improve retinal focus. In June 2023, Vyluma announced United States Food and Drug Administration acceptance of the New Drug Application for NVK002, a low-dose atropine eye drops for pediatric myopia. This development reflects significant progress in pediatric myopia management drugs and highlights advancements in addressing unmet needs in controlling myopia progression among children.
Refractive Errors Epidemiology
The refractive errors pipeline underscores a significant and growing epidemiological burden, driving demand for innovative vision care solutions and targeted therapies. According to Dr. Moushumi Majumder et al., 2025, refractive errors account for 47% of all vision impairment cases in developed countries. Globally, around 12.8 million children aged 9-15 years are affected by refractive error-related visual impairment, reinforcing the need for early-stage eye disorder interventions. In India, the overall incidence is 17.43%, increasing to 22.14% in urban populations compared to 12.71% in rural areas. Among younger populations, incidence ranges from 16.4 to 26.6% in Western countries and 19.4 to 48.1% across Asian regions.Refractive Errors - Pipeline Therapeutic Assessment
This section of the report covers the analysis of refractive errors drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The refractive errors pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Polymer
- Regenerative Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Refractive Errors Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 41%, covers a major share of the total refractive errors clinical trials, reflecting advanced clinical validation, high efficacy potential, and regulatory readiness. Phase II accounts for 32%, driven by dose optimization and safety profiling. Phase IV represents 19%, focusing on post-marketing surveillance and long-term outcomes. This distribution highlights a strong, well-structured pipeline poised to advance innovative therapies and support market growth.Refractive Errors Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the refractive errors pipeline analysis include small molecules, polymers, and regenerative therapies. The refractive errors report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for refractive errors. Atropine-based therapies are leading the pipeline for myopia management in children. For instance, NVK002, a low-dose 0.01% atropine eye drop developed by Vyluma and licensed to Zhaoke Ophthalmology, is under regulatory review in China, the United States, and the European Union. NVK002 has demonstrated significant efficacy and a favorable safety profile in Phase III trials, offering promising treatment to slow myopia progression.Refractive Errors Clinical Trials - Key Players
The report for the refractive errors pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed refractive errors therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in refractive errors clinical trials:- Ocumension (Hong Kong) Limited
- iVeena Delivery Systems, Inc.
- Qilu Pharmaceutical Co., Ltd.
- Sunhawk Vision Biotech, Inc.
- AbbVie Inc.
- Tenpoint Therapeutics, Inc.
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
- Ocuphire Pharma, Inc.
- VIS, Inc.
- CSPC Ouyi Pharmaceutical Co., Ltd.
Refractive Errors - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for refractive errors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of refractive errors drug candidates.Drug: OT-101
OT-101 (Atropine Sulfate 0.01%) is an investigational low-dose ophthalmic solution sponsored by Ocumension (Hong Kong) Limited for the treatment of progressive myopia in pediatric patients. This Phase III study evaluates the safety, tolerability, and efficacy of OT-101 in slowing myopia progression. The drug is a muscarinic receptor antagonist that modulates ocular growth by influencing scleral remodeling and axial elongation. OT-101 is administered topically as an eye drop once daily at bedtime. The study is examining long-term outcomes through randomized, placebo-controlled dosing over multiple years.Drug: IVMED 85
IVMED-85 is a novel, preservative-free prescription ophthalmic solution by iVeena Delivery Systems, Inc. for pediatric progressive myopia. The Phase I/II study evaluates safety and preliminary efficacy while examining improvements in visual acuity and changes in myopia progression over one year. The drug is being administered via the topical ocular route as twice-daily eye drops. IVMED-85 works by activating lysyl oxidase (LOX), thereby strengthening scleral and corneal collagen crosslinking. This mechanism potentially reduces axial elongation and supports improved refractive outcomes compared with placebo.Key Questions Answered in the Refractive Errors Pipeline Insight Report
- Which companies/institutions are leading refractive errors drug development?
- Which company is leading the refractive errors pipeline development activities?
- What is the current refractive errors commercial assessment?
- What are the opportunities and challenges present in the refractive errors pipeline landscape?
- What is the efficacy and safety profile of refractive errors pipeline drugs?
- Which company is conducting major trials for refractive errors drugs?
- Which companies/institutions are involved in refractive errors collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in refractive errors?
Reasons To Buy This Report
The Refractive Errors Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for refractive errors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into refractive errors collaborations, regulatory environments, and potential growth opportunities.Table of Contents
1 Preface
3 Overview of Refractive Errors
4 Patient Profile: Refractive Errors
5 Refractive Errors: Epidemiology Snapshot
6 Refractive Errors: Market Dynamics
7 Refractive Errors: Key Facts Covered
8 Refractive Errors, Drug Pipeline Assessment
9 EMR Drug Pipeline Comparative Analysis
10 Refractive Errors Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Refractive Errors Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Refractive Errors Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Refractive Errors Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Refractive Errors, Key Drug Pipeline Companies
Companies Mentioned
- Drug: OT-101
- Drug: IVMED 85
